نتایج جستجو برای: opioid dependence

تعداد نتایج: 186289  

Journal: :iranian journal of medical sciences 0
elham hakimizadeh physiology-pharmacology research center, rafsanjan university of medical sciences, rafsanjan, iran mohammad kazemi arababadi immunology of infectious diseases research center, rafsanjan university of medical sciences, rafsanjan, iran ali shamsizadeh physiology-pharmacology research center, rafsanjan university of medical sciences, rafsanjan, iran mohammad allahtavakoli physiology-pharmacology research center, rafsanjan university of medical sciences, rafsanjan, iran mohammad ebrahim rezvani department of physiology, school of medicine, shahid sadoughi university of medical sciences, yazd, iran ali roohbakhsh pharmaceutical research center, school of pharmacy, mashhad university of medical sciences, mashhad, iran

background: chronic use of opioids usually results in physical dependence. the underlying mechanisms for this dependence are still being evaluated. transient receptor potential vanilloid type 1 (trpv1) are important receptors of pain perception. their role during opioid dependence has not been studied well. the aim of this study was to evaluate the effect of morphine-dependence on the expressio...

2000
JUN GUO YALAN WU WENBO ZHANG JING ZHAO LAKSHMI A. DEVI GANG PEI

Agonist-induced receptor phosphorylation is an initial step in opioid receptor desensitization, a molecular mechanism of opioid tolerance and dependence. Our previous research suggested that agonist-induced d-opioid receptor (DOR) phosphorylation occurs at the receptor carboxyl terminal domain. The current study was carried out to identify the site of DOR phosphorylation during agonist stimulat...

Journal: :The American journal on addictions 2004
Leslie Amass Walter Ling Thomas E Freese Chris Reiber Jeffrey J Annon Allan J Cohen Dennis McCarty Malcolm S Reid Lawrence S Brown Cynthia Clark Douglas M Ziedonis Jonathan Krejci Susan Stine Theresa Winhusen Greg Brigham Dean Babcock Joan A Muir Betty J Buchan Terry Horton

In October 2002, the U.S. Food and Drug Administration approved buprenorphine-naloxone (Suboxone) sublingual tablets as an opioid dependence treatment available for use outside traditionally licensed opioid treatment programs. The NIDA Center for Clinical Trials Network (CTN) sponsored two clinical trials assessing buprenorphine-naloxone for short-term opioid detoxification. These trials provid...

Journal: :Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2012
Valerie A Gruber Petrie M Rainey David E Moody Gene D Morse Qing Ma Sudha Prathikanti Patricia A Pade Anika A H Alvanzo Elinore F McCance-Katz

BACKGROUND This study examined drug interactions between buprenorphine, a partial opioid agonist used for opioid dependence treatment and pain management, and the protease inhibitors (PIs) darunavir-ritonavir and fosamprenavir-ritonavir. METHODS The pharmacokinetics of buprenorphine and its metabolites and symptoms of opioid withdrawal or excess were compared in opioid-dependent, buprenorphin...

Journal: Addiction and Health 2015
Amir Mohammad Kazemifar Bahman Sadeghi-Sedeh Ghafar‏ ‏Ali Mahmoudi Hassan Solhi, Reza Behzadi Shaabanali Alizadeh,

Background: Acute and chronic pain is prevalent in patients with opioid dependence. Lack of knowledge concerning the complex relationship between pain, opioid use, and withdrawal syndrome can account for the barriers encountered for pain management. This study was designed to evaluate the efficacy of sublingual (SL) buprenorphine for post-operative analgesia, compared with intravenous (IV) morp...

Journal: :Science 2013
Bruce Alberts Roger Beachy David Baulcombe Gunter Blobel Swapan Datta Nina Fedoroff Donald Kennedy Gurdev S Khush Jim Peacock Martin Rees Phillip Sharp

COVER Immunostained fl uorescence microscopy image of a biomarker of endogenous withdrawal (phosphorylated extracellular regulated kinase, red) that increases in mouse spinal cord neurons (green) during opioid receptor blockade (image width: 250 micrometers). Infl ammation or injury to the skin causes μ-opioid receptors to become constitutively active, which leads to long-term relief from chron...

Journal: :Pain 2007
Jane C Ballantyne K Steven LaForge

Throughout the long history of opioid drug use by humans, it has been known that opioids are powerful analgesics, but they can cause addiction. It has also been observed, and is now substantiated by multiple reports and studies, that during opioid treatment of severe and short-term pain, addiction arises only rarely. However, when opioids are extended to patients with chronic pain, and therapeu...

Journal: :CNS & neurological disorders drug targets 2010
Juan F Lopez-Gimenez Graeme Milligan

Internalisation of the mu opioid receptor from the surface of cells is generally achieved by receptor occupancy with agonist ligands of high efficacy. However, in many situations the potent analgesic morphine fails to promote internalisation effectively and whether there is a direct link between this and the propensity for the sustained use of morphine to result in both tolerance and dependence...

Journal: :Neuropharmacology 2000
B Hahn I P Stolerman M Shoaib

The ability of kappa-opioid receptor ligands to modulate dependence-related behavioural effects of drugs like morphine and cocaine is well documented. The present study examined the effects of kappa-opioid agonists on nicotine-induced locomotor stimulation in rats chronically pre-exposed to nicotine (0.4 mg/kg/day). U50,488 [0.5-3 mg/kg subcutaneously (s.c.)], U69,593 [0.08-0.32 mg/kg intraperi...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید